| 产品描述: | Lanadelumab (SHP643) is a human IgG1 monoclonal antibody against plasma kallikrein (pKal) with an Ki value of 0.12 nM. Lanadelumab inhibits both free and HMWK (high molecular weight kininogen)-bound pKal. Lanadelumab has the potential for the research of hereditary angioedema. |
| 靶点: |
KLKB1 |
| 体外研究: |
Lanadelumab (0-1000 nM) inhibits pKal proteolytic activity of single-chain HMWK (its endogenous protein substrate), and addition of Lanadelumab to pKal samples in vitro preventes the proteolysis of HMWK and the consequent release of bradykinin with an IC50 value of 1.3 nM. |
| 体内研究: |
Lanadelumab (20 mg/kg; i.v. or s.c.) shows a long half-life of about 12.5 days and blocks high molecular weight kininogen proteolysis in activated plasma in a dose- and time-dependent manner in cynomolgus monkeys. Lanadelumab (1, 30 mg/kg; s.c.) inhibits carrageenan-induced paw edema in the Male Sprague-Dawley rats . |
| 保存条件: |
2-8°C, 避光, 氮气保存 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
0 ml |
0 ml |
0 ml |
| 5 mM |
0 ml |
0 ml |
0 ml |
| 10 mM |
0 ml |
0 ml |
0 ml |
| 50 mM |
0 ml |
0 ml |
0 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |